Skip to main content
Book cover

Diabetes pp 42–50Cite as

Type 2 Diabetes Mellitus, Pandemic in 21st Century

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 771))

Abstract

In the second half of the 20th century it became obvious that a relentless increase in Type 2 diabetes mellitus (T2DM), affecting the economically affluent countries, is gradually afflicting also the developing world. This chapter shows the threat that the T2DM epidemic represents to mankind, with the astonishing recent discoveries on the role of obesity and of body fat in this metabolic disorder. Presently, the highest prevalence of T2DM is in Saudi Arabia. T2DM is very high in over 10% of adults in the USA, Switzerland and Austria. Prevalence is low in Norway, China and in Iceland. Predictions of epidemiologists for the first third of the 21st century claim up to 2.5 times increase in the prevalence of T2DM in the Middle East, Sub-Saharan Africa, India, rest of Asia and in the Latin America. In China the number of patients with T2DM will double in 2030. In the economically advanced countries the increase will be about 50% in 2030.

Increasing urbanization, aging populations, obesity and falling levels of physical activity are all contributing to the rise of T2DM worldwide. The main cause of T2DM pandemic is growing prevalence of obesity in Europe and USA. In the North America and European Union countries obesity is considered to be responsible for up to 70–90% of T2DM in adult population. The precise mechanism by which obesity leads to insulin resistance and to T2DM is not completely known but it may be related to several biochemical factors such as abnormalities in free fatty acids, adipokines, leptin and other substances.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Diabetes Atlas, International Diabetes federation, USA, 2007.

    Google Scholar 

  2. Roglic G, Green A et al. Prevalence of diabetes. Estimates for the year 2000 and projection for 2030. Diabetes Care 2004; 27:1047–1053.

    Article  PubMed  Google Scholar 

  3. WHO. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Geneva, Switzerland, 2009.

    Google Scholar 

  4. CDC. Centres for Disease Control and Prevention. Atlanta, USA, 2007.

    Google Scholar 

  5. James WPT, Jackson-leach R, Mhurdu CN et al. Overweight and obesity. In: Ezzati M, Lopez AD, Rodgers A et al, eds. Comparative Quantification of Health Risks. WHO, Geneva, 2003.

    Google Scholar 

  6. Basdevant A, Ciangura C. Obesity, a disease. Bull Acad Natl Med 2010; 194(10):13–20.

    PubMed  Google Scholar 

  7. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res 2010; 107(5):579–591.

    Article  CAS  PubMed  Google Scholar 

  8. Boden G. Obesity and free fatty acids. Endocrinol Metab clin North Amer 2008; 37(3):635–646.

    Article  CAS  Google Scholar 

  9. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab rep 2006; 6(sn3):177–181.

    Article  CAS  PubMed  Google Scholar 

  10. Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007; 24(9):934–945.

    Article  CAS  PubMed  Google Scholar 

  11. Ioannidis I. The road from obesity to type 2 diabetes. angiology 2008; 59(2 Suppl):39S–43S.

    Article  PubMed  Google Scholar 

  12. lele RD. Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players in type 2 diabetes mellitus. J Assoc Physicians India 2010; 58:35–40.

    Google Scholar 

  13. Rasouli N, kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1):S64–S73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. keller U. From obesity to diabetes. Int J Vitam Nutr res 2006; 76(4): 172–177.

    Article  CAS  PubMed  Google Scholar 

  15. Dardeno TA, Chou SH, Moon HS et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31(3):377–393.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Viollet B, Lantier L, Devin-Leclerc J et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci 2009; 14:3380–3400.

    Article  CAS  Google Scholar 

  17. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116(7):1776–1783.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes2008;32Suppl 4:S712.

    Google Scholar 

  19. Christian M, Parker MG. the engineering of brown fat. J Molec cell Biol 2010; 2(1):23-25.

    Article  CAS  Google Scholar 

  20. Ginter E, Simko V. adult obesity at the beginning of the 21st century: epidemiology, pathophysiology and health risk. Bratisl Lek Listy 2008; 109(5):224–230.

    CAS  PubMed  Google Scholar 

  21. Cypess AM, Lehman S, Williams G et al. Identification and importance of brown adipose tissue in adult humans. New Eng J Med 2009; 360:1509–1517.

    Article  CAS  PubMed  Google Scholar 

  22. De la Monte SM, Longato L, Tong M et al. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. curr opin Investig Drugs 2009; 10(10):1049–1060.

    Google Scholar 

  23. Daniels SR, Jacobson MS, Mccrindle BW et al. American heart association childhood obesity research Summit: executive summary. Circulation 2009; 119(15):2114–2123.

    Article  PubMed  Google Scholar 

  24. Gordon-larsen P, Boone-Heinon J, Sidney S et al. Active commuting and cardiovascular disease risk. the CARDIA study. Arch Intern Med 2009; 169:1216–1223.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ferencik M, Hulin I. Obesity, fatty tissue and inflammation. Med Monitor 2008; 4:16.

    Google Scholar 

  26. Mudaliar S, henry RR. Incretin therapies: Effects beyond glycemic control. am J Med 2009; 122:S25–S36.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Emil Ginter .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Ginter, E., Simko, V. (2013). Type 2 Diabetes Mellitus, Pandemic in 21st Century. In: Ahmad, S.I. (eds) Diabetes. Advances in Experimental Medicine and Biology, vol 771. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5441-0_6

Download citation

Publish with us

Policies and ethics